Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07528157 · ClinicalTrials.gov registry record · NA
Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression
A NA study, sponsored by Stanford University.
- Not yet
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT07528157: Clinical Trial NA study, sponsored by Stanford University.
NCT07528157 is a NA study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07528157, a NA study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study tests whether a brain stimulation treatment for depression called intermittent theta burst stimulation (iTBS) can be improved by tailoring it to each individual. A type of brain signal measured with electroencephalography (EEG) after a single pulse of brain stimulation, called an early local TMS-evoked potential (EL-TEP), is used to identify which stimulation settings work best for each participant. The investigators will compare individualized (personalized) iTBS settings to standard (non-personalized) settings and to inactive (sham) stimulation. Participants are adults with treatment-resistant depression.
Primary Outcome
EL-TEP amplitude is the peak-to-trough amplitude of the early (20-60 ms) EEG response recorded over the left dorsolateral prefrontal cortex following single TMS pulses. Percent change is calculated from pre-iTBS to post-iTBS for each stimulation condition.
Interventions
- DEVICE Sham iTBS
- DEVICE Personalized iTBS
- DEVICE Non-Personalized iTBS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What is known before NCT07528157 opens enrollment
NCT07528157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Sham iTBS is the first listed.
NCT07528157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07528157 about?
NCT07528157 is a clinical study titled "Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression". This study tests whether a brain stimulation treatment for depression called intermittent theta burst stimulation (iTBS) can be improved by tailoring it to each individual. A type of brain signal measured with electroencephalography (EEG) after a single pulse of brain stimulation, called an early lo...
What is the current status of trial NCT07528157?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2026-06-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07528157?
The interventions under investigation include: Sham iTBS (DEVICE), Personalized iTBS (DEVICE), Non-Personalized iTBS (DEVICE).
Who is sponsoring clinical trial NCT07528157?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07528157's enrollment target sits among peer trials
80 994th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI